U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Membe SK, Coyle D, Husereau D, et al. Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2011 Mar.

Cover of Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis

Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Internet].

Show details

REFERENCES

1.
Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev. 2000;14(2):94–110. [PubMed: 11012252]
2.
Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent-detergent-treated fresh-frozen plasma. Vox Sang. 2003;85(2):88–95. [PubMed: 12925160]
3.
Expert Working Group. Guidelines for red blood cell and plasma transfusion for adults and children. CMAJ. 1997. [accessed 2008 Mar 19]. pp. S1–S24. Available: http://www​.cmaj.ca/cgi/data/156/11/DC1/6.
4.
Hui CH, Williams I, Davis K. Clinical audit of the use of fresh-frozen plasma and platelets in a tertiary teaching hospital and the impact of a new transfusion request form. Intern Med J. 2005;35(5):283–288. [PubMed: 15845110]
5.
Shanberge JN, Quattrociocchi-Longe T. Analysis of fresh frozen plasma administration with suggestions for ways to reduce usage. Transfus Med. 1992;2(3):189–194. [PubMed: 1308829]
6.
Tobin SN, Campbell DA, Boyce NW. Durability of response to a targeted intervention to modify clinician transfusion practices in a major teaching hospital. Med J Aust. 2001;174(9):445–448. [PubMed: 11386588]
7.
Metz J, McGrath KM, Copperchini ML, Haeusler M, Haysom HE, Gibson PR, et al. Appropriateness of transfusions of red cells, platelets and fresh frozen plasma. An audit in a tertiary care teaching hospital. Med J Aust. 1995;162(11):572–573. [PubMed: 7791642]
8.
Hutton B, Fergusson D, Tinmouth A, McIntyre L, Kmetic A, Hébert PC. Transfusion rates vary significantly amongst Canadian medical centres. Can J Anaesth. 2005;52(6):581–590. [PubMed: 15983142]
9.
Goodnough LT, Johnston MF, Toy PT. The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group. JAMA. 1991;265(1):86–90. [PubMed: 1984129]
10.
Luk C, Eckert KM, Barr RM, Chin-Yee IH. Prospective audit of the use of fresh-frozen plasma, based on Canadian Medical Association transfusion guidelines. CMAJ. 2002. [accessed 2007 Dec 10]. pp. 1539–1540. Available: http://www​.pubmedcentral​.nih.gov/articlerender​.fcgi?tool=pubmed&pubmedid=12074120. [PMC free article: PMC113799] [PubMed: 12074120]
11.
Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003;17(2):120–162. [PubMed: 12733105]
12.
Clinical Guide to Transfusion. 4th ed. Toronto: Canadian Blood Services; Jul, 2007. [accessed 2008 Feb 6]. Canadian Blood Services. Available: http://209​.217.107.132/Web/tmws​.nsf/resources​/CBC_CGT/$file/CBS-CGT-BM.pdf.
13.
Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion. 2001;41(1):130–135. [PubMed: 11161258]
14.
Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev. 2005;19(1):2–31. [PubMed: 15830325]
15.
Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med. 2007;33 Suppl 1:S17–S21. [PubMed: 17676435]
16.
Gresens CJ, Holland PV. Other reactions and alloimmunization. In: Linden JV, Bianco C, editors. Blood Safety and Surveillance. New York: Marcel Dekker; 2001. pp. 71–86.
17.
AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA. 1994;272(15):1210–1214. [PubMed: 7933351]
18.
Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion. 1999;39(5):479–487. [PubMed: 10335997]
19.
Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components. Pathogen inactivation of labile blood products. Transfus Med. 2001;11(3):149–175. [PubMed: 11422945]
20.
Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98(3):630–638. [PubMed: 12650799]
21.
Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol. 2001;96(2):579–583. [PubMed: 11232711]
22.
El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention: results from a disease model. Eur J Health Econ. 2005;6(2):159–165. [PubMed: 15761777]
23.
Gagnon YM, Levy AR, Iloeje UH, Briggs AH. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol. 2004;38(10 Suppl):S179–S186. [PubMed: 15602168]
24.
Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine. 2007;25(51):8536–8548. [PubMed: 17996339]
25.
Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991–2001. AIDS. 2004;18(18):2411–2418. [PubMed: 15622317]
26.
Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005. [accessed 2007 Dec 21]. pp. 821–831. Available: http://www​.annals.org​/cgi/reprint/142/10/821.pdf. [PubMed: 15897532]
27.
Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics. 1997;12(1):54–66. [PubMed: 10169387]
28.
Riedler GF, Haycox AR, Duggan AK, Dakin HA. Solvent-detergent-treated plasma may be cost-effective [letter] Vox Sang. 2003;84(4):334–335. [PubMed: 12757510]
29.
Angus DC, Musthafa AA, Clermont G, Griffin MF, Linde-Zwirble WT, Dremsizov TT, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001. [accessed 2007 Dec 21]. pp. 1389–1394. Available: http://ajrccm​.atsjournals​.org/cgi/reprint/163/6/1389. [PubMed: 11371406]
30.
Smith KJ, Roberts MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. Am J Med. 2000;108(9):723–729. [PubMed: 10924649]
31.
About the OCCI. Toronto: The Ontario Case Costing Initiative; 2007. [accessed 2007 Dec 7]. Available: http://www​.occp.com/
32.
Octaplas solvent-detergent (S/D) treated human plasma: 200 mL [product monograph]. Brampton (ON): Octapharma Canada Inc.; 2006.
33.
Burnouf T. Modern plasma fractionation. Transfus Med Rev. 2007;21(2):101–17. [PMC free article: PMC7125842] [PubMed: 17397761]
34.
Ho C, Membe S, Cimon K, Roifman C, Kanani A. Overview of subcutaneous versus intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. [accessed 2008 Feb 6]. Available: http://cadth​.ca/media​/pdf/466_Immunoglobulin-Primary-Immunodefiencies_to_e.pdf.
35.
Business Briefs. International Blood/Plasma News. 2007. [accessed 2008 Feb 27]. pp. 166–170. Available: http://www​.marketingresearchbureau​.com/IBPN0707.pdf.
36.
Albumin Therapy: Clinical Library Slide Kit. Deerfield (IL): Baxter Healthcare; 2008. [accessed 2008 Feb 26]. Albumin Slides - Availability [presentation slides] Available: http://www​.albumintherapy​.com/us/en/pdf/slidekit​/AlbuminSlides_avail.pdf.
37.
Colgan K, Moody ML, Witte K. Responsible use of blood products in response to supply and demand. Am J Health Syst Pharm. 2000;57(22):2094–2098. [PubMed: 11098311]
Copyright © 2011 CADTH.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK298932
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.4M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...